Array BioPharma products
BRAFTOVI (encorafenib) + MEKTOVI (binimetinib)
Indication: BRAF V600E/V600K unresectable or metastatic melanoma—first approved as a combination therapy; being studied in a targeted triplet regimen for BRAF-mutant metastatic colorectal cancer as part of Array’s core oncology franchise
Additionally, Array has been instrumental in discovering or developing the following impactful oncology agents—each subsequently licensed or approved by partner organizations under different brand names:
-
KRAZATI (adagrasib) – KRAS G12C inhibitor
-
TUKYSA (tucatinib) – HER2-targeted therapy
-
KOSELUGO (selumetinib) – MEK1/2 inhibitor
-
VITRAKVI (larotrectinib) – TRK fusion inhibitor
-
RETEVMO (selpercatinib) – RET inhibitor
-
GANOVO (danoprevir) – HCV protease inhibitor (approved in China)
Array also advanced several clinical-stage pipeline candidates prior to acquisition, including:
-
Filanesib (ARRY-520) – KSP inhibitor investigated in multiple myeloma
-
ARRY-797 – p38 inhibitor explored in LMNA-related dilated cardiomyopathy
Array was acquired by Pfizer in mid-2019 and folded into its Oncology R&D infrastructure, significantly enhancing Pfizer’s targeted small-molecule cancer portfolio.
No comments:
Post a Comment